Isodiol International Inc ISOLF

RE:RE:RE:RE:RE:RE:Not profitable

[Mazzanazzam]

or maybe it's time for you to learn to read in general.

VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the Company or Isodiol), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, reports unaudited Q3 revenues for the period ended December 31, 2017 of $5.89 million CDN a for net operational profit of $202,254 CDN. In comparison to the fiscal Q2 revenues, Q3 represents a 16% increase. The company is very pleased to report these revenues and attributes the growth and profit increase to increased distribution, reduced manufacturing costs, portfolio diversification, and the continued integration of wholly owned subsidiaries. Since the beginning of fiscal Q4, which commenced January 1, the Company has continued to gain traction in international markets such as Latin America and Europe and will continue to pursue additional global expansion. The Company has also made significant traction in operations with wholly owned subsidiaries such as ISO-Sport, Be Tru Wellness, and Bradleys Bioscience.